WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • WJPPS: MARCH ISSUE PUBLISHED
  • March Issue has been successfully launched on 1 March 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

Abstract

MOUTH DISSOLVING TABLETS CHALLENGES, PREPARATION STRATEGIES WITH A SPECIAL EMPHASIS ON LOSARTAN POTASSIUM – A REVIEW

Pankaj Bhatt*

ABSTRACT

The main purpose of this review article is to provide complete information about the mouth dissolving/disintegrating tablets (MDTs) of losartan Potassium. Conventional tablets cannot be taken without water. Tablet or capsule cannot be taken by the patient without using water or any other liquid. The problem in swallowing, dysphagia, is common is patient of all age groups, especially pediatrics and geriatrics. Fast dissolving Tablets are swallowed and can get dissolve in the saliva without water and these are true fast dissolving tablets. Rest contain agents to prepare the rate of tablet disintegration in the oral cavity, and is referred to as fast disintegrating tablets because they make take at least a minute to completely disintegrated. Losartan potassium is an active medicine of non-peptidergic angiotensin II receptor antagonist. It is the first new class of drugs to be introduced for clinical use in hypertension. In patients with mild to moderate hypertension, losartan potassium 50 to 100mg once used daily as monotherapy lowers blood pressure to a similar degree to enalapril, atenolol and felodipine extended release (ER). However, with its novel mechanism of action, good efficacy and favorable tolerability profile, losartan potassium is well placed to claim a prominent position in the management of patients with essential hypertension in the future.

Keywords: MDDS, losartan potassium, conventional drug delivery system, direct compression method.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More